A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...